An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized - 01/03/14
Doi : 10.1016/j.jaci.2013.10.015
| Disclosure of potential conflict of interest: The Allergy Center, Odense University Hospital, is participating in the Asteria1 project (Q4881g) on treatment with omalizumab. E. Eller has received one or more payments for lecturing from or is on the speakers' bureau for Thermo Fisher. C. Bindslev-Jensen is a board member for Novartis; has consultancy arrangements with Novartis and MSD; and has received one or more payments for lecturing from or is on the speakers' bureau for Novartis, MSD, and Thermo Fisher. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2013
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 133 - N° 3
P. 914 - mars 2014 Retour au numéro
Article précédent
- Allergen microarray detects high prevalence of asymptomatic IgE sensitizations to tropical pollen-derived carbohydrates
- Clarissa R. Cabauatan, Christian Lupinek, Sandra Scheiblhofer, Richard Weiss, Margarete Focke-Tejkl, Prem L. Bhalla, Mohan B. Singh, Paul A. Knight, Marianne van Hage, John Donnie A. Ramos, Rudolf Valenta
- Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program
- Kenneth Wysocki, Seo Young Park, Eugene Bleecker, William Busse, Mario Castro, Kian Fan Chung, Benjamin Gaston, Serpil Erzurum, Elliot Israel, W. Gerald Teague, Charity G. Moore, Sally Wenzel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?